Jonathan Fox, M.D., Ph.D., is president and chief medical officer of Eidos Therapeutics. He is an experienced pharmaceutical executive and established industry leader. Before joining Eidos, he was chief medical officer for MyoKardia Inc., and held senior roles with AstraZeneca, Merck and GlaxoSmithKline. With nearly 20 years’ experience across all clinical and regulatory phases of drug development, he has participated in the development, registration, and post-marketing support of numerous products for heritable cardiomyopathies, acute coronary syndrome, heart failure, hypertension, dyslipidemias, arrhythmias, diabetes, and other disorders.
Dr. Fox is a board-certified cardiologist with basic science training and experience. He received his A.B., Ph.D., and M.D. degrees from the University of Chicago, completed his training in Internal Medicine and Cardiology at Duke University, and was on the faculty of the University of Pennsylvania School of Medicine. Dr. Fox is currently adjunct professor at Stanford University School of Medicine and is a long-serving Trustee of the Lankenau Institute for Medical Research. He enjoys living in San Francisco and being part of the vibrant Bay Area medical and biotechnology community.
What is Jonathan C. Fox's net worth?
The estimated net worth of Jonathan C. Fox is at least $1.33 million as of December 26th, 2023. Dr. Fox owns 10,857 shares of Eidos Therapeutics stock worth more than $1,326,834 as of May 14th. This net worth approximation does not reflect any other investments that Dr. Fox may own. Learn More about Jonathan C. Fox's net worth.
How old is Jonathan C. Fox?
How do I contact Jonathan C. Fox?
Has Jonathan C. Fox been buying or selling shares of Eidos Therapeutics?
Jonathan C. Fox has not been actively trading shares of Eidos Therapeutics in the last ninety days. Most recently, Jonathan C. Fox sold 3,122 shares of the business's stock in a transaction on Wednesday, September 16th. The shares were sold at an average price of $50.16, for a transaction totalling $156,599.52. Following the completion of the sale, the insider now directly owns 3,294 shares of the company's stock, valued at $165,227.04. Learn More on Jonathan C. Fox's trading history.
Who are Eidos Therapeutics' active insiders?
